Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06854224 · ClinicalTrials.gov registry record · Phase 2
Orexin Antagonism for Suicide Risk: A Proof-of-Concept Clinical Trial
A Phase 2 study of Major Depressive Disorder (MDD) and Suicide Risk, sponsored by Marianne Goodman.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT06854224: Recruiting Phase 2 study of Major Depressive Disorder (MDD) and Suicide Risk, sponsored by Marianne Goodman.
NCT06854224 is a Phase 2 study of Major Depressive Disorder (MDD) and Suicide Risk that is actively recruiting participants, run by Marianne Goodman. The registered enrollment target is 30 participants, below the 157-participant average among 22 other Major Depressive Disorder (MDD) trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06854224, a Phase 2 study of Major Depressive Disorder (MDD) and Suicide Risk, is actively recruiting participants, sponsored by Marianne Goodman.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this proof-of-concept clinical trial is to evaluate the initial safety, feasibility, and tolerability of the orexin mixed antagonist suvorexant in a sample of veteran adults with Major Depressive Disorder and elevated suicide risk. The main question it aims to answer is: Is Suvorexant safe, feasible, and tolerable for participants? Participants will: * Take Surovexant every day for four weeks (10mg in the first two weeks and 20mg in the second two weeks) * Visit the medical center at the beginning of the study (week 1), after taking Suvorexant for two weeks (week 3) and following the full Suvorexant dose (week 5) for in-person assessments. * Fill out self-report assessments (remotely) at week 2 (after one week of Suvorexant) and week 4 (after three weeks of Surovexant)
Primary Outcome
Implicit Association Tests ( IATs) use reaction time (RT) to capture automatic, implicit processes to gauge implicit self-identification with a construct of interest. Participants classify stimuli presented in the center of the screen into categories. The category labels are located on the left and right of the screen and participants classify stimuli by selecting keys corresponding to the left or right. RTs are measured as participants complete this task thereby gauging implicit mental associat
Conditions Studied
Interventions
- DRUG Suvorexant (dual orexin receptor antagonist)
Study Locations (1)
New York
- James J. Peters Veterans Affairs Medical Center - The Bronx
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-09-01 |
| Est. Completion | 2027-07-01 |
| Phase | Phase 2 |
What NCT06854224 shows while recruiting
NCT06854224 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 157-participant average among 22 other Major Depressive Disorder (MDD) trials with a reported enrollment target (81% lower).
The record links to 2 conditions, with Major Depressive Disorder (MDD) appearing as the primary indexed condition, and to 1 intervention - of which Suvorexant (dual orexin receptor antagonist) is the first listed.
NCT06854224 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT06854224 about?
NCT06854224 is a clinical study titled "Orexin Antagonism for Suicide Risk: A Proof-of-Concept Clinical Trial". The goal of this proof-of-concept clinical trial is to evaluate the initial safety, feasibility, and tolerability of the orexin mixed antagonist suvorexant in a sample of veteran adults with Major Depressive Disorder and elevated suicide risk. The main question it aims to answer is: Is Suvorexant sa...
What is the current status of trial NCT06854224?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2025-09-01. Estimated completion is 2027-07-01.
What conditions does trial NCT06854224 study?
This clinical trial studies the following conditions: Major Depressive Disorder (MDD), Suicide Risk.
What interventions are being tested in trial NCT06854224?
The interventions under investigation include: Suvorexant (dual orexin receptor antagonist) (DRUG).
Who is sponsoring clinical trial NCT06854224?
This trial is sponsored by Marianne Goodman, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06854224 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Major Depressive Disorder (MDD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06854224's enrollment target sits among peer trials
30 17th of 22 higher than 6 of 22 other Major Depressive Disorder (MDD) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Major Depressive Disorder (MDD) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response
RECRUITING · Phase 2
-
A Study to Evaluate the Effectiveness of DT-101 in Patients With Depression
RECRUITING · Phase 2
-
A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)
RECRUITING · Phase 2
-
Study to Evaluate Efficacy and Safety of Ropanicant in MDD Patients
ACTIVE NOT RECRUITING · Phase 2
-
A Study in Patients With Major Depressive Disorder
ACTIVE NOT RECRUITING · Phase 2
-
Improving Depression Outcome by Enhancing Memory for Cognitive Therapy
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI